All Names： Apalutamide，Erleada
Indications：1. Metastatic castration-sensitive prostate cancer (mCSPC); 2. Non-metastatic castration-resistant prostate cancer (nmCRPC)
Manufacturer：Beacon Medicines, Bangladesh
Customs Clearance Procedure：If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE（适应症）
ERLEADA is indicated for the treatment of patients with:
Metastatic castration-sensitive prostate cancer (mCSPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC)
The recommended dose of ERLEADA is 240 mg (four 60 mg tablets) administered orally once daily. Swallow the tablets whole. ERLEADA can be taken with or without food.
Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
Cerebrovascular and Ischemic Cardiovascular Events
For full information, please refer to: